

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 December 2023 (07.12.2023)



(10) International Publication Number
WO 2023/235897 A2

- (51) **International Patent Classification:**
C12N 15/86 (2006.01) C12N 9/00 (2006.01)
- (21) **International Application Number:**
PCT/US2023/067948
- (22) **International Filing Date:**
05 June 2023 (05.06.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/348,856 03 June 2022 (03.06.2022) US
63/383,026 09 November 2022 (09.11.2022) US
- (71) **Applicant: OYSTER POINT PHARMA, INC.** [US/US];
202 Carnegie Center, Suite 109, Princeton, NJ 08540 (US).
- (72) **Inventors: CARLSON, Eric, C.;** c/o Oyster Point Pharma,
Inc., 202 Carnegie Center, Suite 109, Princeton, NJ 08540
(US). **NAU, Jeffrey, Alan;** c/o Oyster Point Pharma, Inc.,
202 Carnegie Center, Suite 109, Princeton, NJ 08540 (US).
- (74) **Agent: SCARPATI, Michael et al.;** Arent Fox Schiff LLP
(NY), 1717 K Street, NW, Washington, DC 20006-5344
(US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** AAV VECTOR ENCODING DIAMINE OXIDASE AND USES THEREOF




FIG. 1A

(57) **Abstract:** Provided are recombinant adeno-associated virus (rAAV) vectors, methods of treating a condition (e.g., an ocular condition), pharmaceutical compositions, and other compositions and methods, in which the rAAV vector comprises a polynucleotide encoding diamine oxidase (DAO). Methods of treatment may include administration to the lacrimal gland.

[Continued on next page]

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*